Peptides Similar to Ziconotide
Compare Ziconotide with related peptides and alternatives
📌TL;DR
- •3 similar peptides identified
- •BPC-157: Low - Both are peptides studied for pain-related conditions but with entirely different mechanisms and routes
- •DSIP: Low - Both are peptides with some analgesic research but through entirely different mechanisms
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| Ziconotide (current) | - | - |
| BPC-157 | Low - Both are peptides studied for pain-related conditions but with entirely different mechanisms and routes | Ziconotide is a 25-amino acid cone snail venom peptide blocking N-type calcium channels via intrathecal delivery, while BPC-157 is a 15-amino acid gastric pentadecapeptide with tissue-healing properties administered subcutaneously or orally. |
| DSIP | Low - Both are peptides with some analgesic research but through entirely different mechanisms | Ziconotide targets N-type calcium channels intrathecally for severe chronic pain, while DSIP modulates sleep architecture and has investigational analgesic properties through poorly defined mechanisms. |
| Selank | Low - Both are peptides with neurological applications but target different conditions and pathways | Ziconotide blocks calcium channels in the spinal cord for pain, while selank is a tuftsin analog modulating GABAergic signaling for anxiety. Different indications, mechanisms, and delivery routes. |
BPC-157Low - Both are peptides studied for pain-related conditions but with entirely different mechanisms and routes
Differences
Ziconotide is a 25-amino acid cone snail venom peptide blocking N-type calcium channels via intrathecal delivery, while BPC-157 is a 15-amino acid gastric pentadecapeptide with tissue-healing properties administered subcutaneously or orally.
Advantages
Systemic administration, tissue healing properties, anti-inflammatory effects, minimal CNS side effects
Disadvantages
No FDA approval, not a direct analgesic, limited human clinical trial data, different pain indications
DSIPLow - Both are peptides with some analgesic research but through entirely different mechanisms
Differences
Ziconotide targets N-type calcium channels intrathecally for severe chronic pain, while DSIP modulates sleep architecture and has investigational analgesic properties through poorly defined mechanisms.
Advantages
Systemic administration, sleep-promoting properties, stress modulation
Disadvantages
No clinical approval, poorly defined mechanism, limited clinical evidence for pain, no RCTs for analgesic efficacy
SelankLow - Both are peptides with neurological applications but target different conditions and pathways
Differences
Ziconotide blocks calcium channels in the spinal cord for pain, while selank is a tuftsin analog modulating GABAergic signaling for anxiety. Different indications, mechanisms, and delivery routes.
Advantages
Intranasal delivery, anxiolytic effects, approved in Russia, favorable safety profile
Disadvantages
Not an analgesic, different clinical indication, not approved outside Russia
Peptides Related to Ziconotide#
Ziconotide occupies a unique position in peptide therapeutics as the only FDA-approved peptide analgesic delivered intrathecally. Its mechanism of selective N-type calcium channel blockade is distinct from all other therapeutic peptides. No other peptide has the same indication or mechanism, so comparisons are limited to peptides with tangentially related neurological or pain applications.
BPC-157#
BPC-157 (body protection compound-157) is a gastric pentadecapeptide studied for tissue healing and anti-inflammatory effects. While both are peptides with some relevance to pain conditions, their mechanisms and applications are fundamentally different. BPC-157 addresses pain indirectly through tissue repair and inflammation reduction, while ziconotide directly blocks pain signal transmission. BPC-157 has the advantage of multiple administration routes but lacks FDA approval and rigorous clinical trial data.
DSIP#
DSIP (delta sleep-inducing peptide) is an endogenous neuropeptide with sleep-promoting and stress-modulatory properties. Early research explored analgesic effects, but the evidence is limited and the mechanism poorly defined. Unlike ziconotide with its well-characterized calcium channel target, DSIP's receptor pharmacology remains unclear.
Selank#
Selank is a synthetic tuftsin analog approved in Russia for anxiety. While both target CNS conditions, selank addresses anxiety through GABAergic modulation while ziconotide addresses pain through calcium channel blockade. There is no overlap in clinical indications.
Summary Comparison#
| Feature | Ziconotide | BPC-157 | DSIP | Selank |
|---|---|---|---|---|
| Mechanism | N-type Ca2+ channel block | Tissue healing / anti-inflammatory | Undefined | GABAergic / tuftsin |
| Primary application | Severe chronic pain | Tissue repair | Sleep / stress | Anxiety |
| Clinical status | FDA approved | Preclinical | Preclinical | Approved (Russia) |
| Route | Intrathecal | SC / Oral | IV / SC | Intranasal |
| Key advantage | Proven non-opioid analgesic | Systemic, multi-tissue | Sleep regulation | Anxiolytic |
Comparison Context#
Ziconotide belongs to the Pain category of research peptides. Comparing Ziconotide with related compounds helps researchers understand its relative positioning in the therapeutic landscape. Each compound has distinct advantages and limitations that should be considered based on the specific research question or clinical need.
Detailed Comparisons#
The following peptides and compounds are most closely related to Ziconotide in mechanism, indication, or therapeutic category:
Ziconotide vs BPC-157#
Similarity: Low - Both are peptides studied for pain-related conditions but with entirely different mechanisms and routes
Key Differences: Ziconotide is a 25-amino acid cone snail venom peptide blocking N-type calcium channels via intrathecal delivery, while BPC-157 is a 15-amino acid gastric pentadecapeptide with tissue-healing properties administered subcutaneously or orally.
Advantages of BPC-157: Systemic administration, tissue healing properties, anti-inflammatory effects, minimal CNS side effects
Disadvantages of BPC-157: No FDA approval, not a direct analgesic, limited human clinical trial data, different pain indications
Researchers choosing between Ziconotide and BPC-157 should consider the development stage, available evidence, and specific research objectives when making their selection.
Ziconotide vs DSIP#
Similarity: Low - Both are peptides with some analgesic research but through entirely different mechanisms
Key Differences: Ziconotide targets N-type calcium channels intrathecally for severe chronic pain, while DSIP modulates sleep architecture and has investigational analgesic properties through poorly defined mechanisms.
Advantages of DSIP: Systemic administration, sleep-promoting properties, stress modulation
Disadvantages of DSIP: No clinical approval, poorly defined mechanism, limited clinical evidence for pain, no RCTs for analgesic efficacy
Researchers choosing between Ziconotide and DSIP should consider the development stage, available evidence, and specific research objectives when making their selection.
Ziconotide vs Selank#
Similarity: Low - Both are peptides with neurological applications but target different conditions and pathways
Key Differences: Ziconotide blocks calcium channels in the spinal cord for pain, while selank is a tuftsin analog modulating GABAergic signaling for anxiety. Different indications, mechanisms, and delivery routes.
Advantages of Selank: Intranasal delivery, anxiolytic effects, approved in Russia, favorable safety profile
Disadvantages of Selank: Not an analgesic, different clinical indication, not approved outside Russia
Researchers choosing between Ziconotide and Selank should consider the development stage, available evidence, and specific research objectives when making their selection.
Related Reading#
Frequently Asked Questions About Ziconotide
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer